HANSEN-TECHNOLOGIES
17.8.2021 15:02:07 CEST | Business Wire | Press release
Hansen Technologies (ASX:HSN) is pleased to announce today that it has signed a new agreement with wilhelm.tel GmbH, a multi-service provider of telecommunications services in Germany.
Under the terms of this agreement, Hansen will upgrade wilhelm.tel’s existing version of Hansen CCB–NavibillingCX to the latest version and replace their existing CRM system. As a result of this upgrade, wilhelm.tel will receive enhanced customer care, billing and product management capabilities, as well as improved accounting and provisioning processes.
Jens Seedorff, General Manager, wilhelm.tel, commented: “Our partnership with Hansen has a strong track record of operational efficiency. It was based on this that we decided that Hansen were the ideal vendor to help further enable the next chapter of our digital transformation initiative – as we confront not only changing customer expectations, but a telecommunications industry undergoing a major degree of transition as well.”
Scott Weir, Regional President, EMEA, Hansen Technologies, commented : “wilhelm.tel is a longstanding customer of Hansen, supporting their customers for over twenty years with our NavibillingCX product. We are excited to have been selected to not only upgrade wilhelm.tel to our new version of NavibillingCX – based on Microsoft Business Central – but also introduce significant new functionality that improves the customer experience, while accelerating time-to-market. wilhelm.tel’s commitment to Hansen and our product demonstrates the strength of our relationship and provides a strong foundation to future-proof their business for many years to come.”
Hansen CCB , part of the Create-Deliver-Engage Suite of software, provides flexible rating, billing and customer care for communications and pay-TV service providers. Part of the Hansen CCB product family, NavibillingCX is a tailor-made unified solution for fixed and mobile telephony, as well as broadband, IP services, cable TV and interconnect billing. It provides end-to-end customer lifecycle management, and also delivers full ERP capabilities including financial controls, reporting and analytics via Microsoft integration.
For further information about Hansen Technologies, please visit www.hansencx.com .
About Hansen Technologies
Hansen Technologies (ASX: HSN) is a leading global provider of software and services to the energy, water and communications industries. With its award-winning software portfolio, Hansen serves 580+ customers in over 80 countries, helping them to create, sell, and deliver new products and services, manage and analyze customer data, and control critical revenue management and customer support processes.
For more information, visit www.hansencx.com
About wilhelm.tel
Founded in 1999 as a completely owned subsidiary of Stadtwerke Norderstedt, wilhelm.tel GmbH is a nationwide pioneer among operators of high-performance fiber optic networks. From the very beginning, the company has consistently followed a Fiber-to-the-Building strategy, directly connecting every building to its fiber optic network. Since 2020, wilhelm.tel has been increasingly laying fiber optics right up to apartment buildings, thus guaranteeing maximum bandwidth to the customer.
The fiber-optic network, which currently comprises around 2,500 kilometers, has long since crossed the city limits of its home market in Norderstedt and is growing steadily in the direction of Schleswig-Holstein, Hamburg and Lower Saxony. wilhelm.tel regularly sets new standards nationwide with pioneering technology and products and services that are precisely tailored to customer needs. With a resulting market share of up to 90 per cent, wilhelm.tel is considered the most sought-after provider in the Hamburg metropolitan region.
In 2019, wilhelm.tel GmbH, with 130 employees, generated an annual turnover of 73 million euros.
For more information on Wilhelm.tel, visit https://www.wilhelm-tel.de/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210817005190/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom